Edgewise Therapeutics, Inc. (EWTX) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $31.58: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10 and A.R:R 1.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Elevated put/call ratio: 17.23; Below-average business quality.
Edgewise Therapeutics is a clinical-stage biopharmaceutical company developing small molecule therapies for rare muscle diseases, with lead candidate sevasemten in late-stage trials for Duchenne and Becker muscular dystrophies. No products approved and no revenue to date;... Read more
Sell if holding. Engine safety override at $31.58: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10 and A.R:R 1.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Elevated put/call ratio: 17.23; Below-average business quality. Chart setup: RSI 52 mid-range, Bollinger mid-band. Score 4.6/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 79d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent Developments — Edgewise Therapeutics, Inc.
Latest news
- Edgewise Therapeutics Q1 EPS $(0.46) Beats $(0.50) Estimate — benzinga May 7, 2026 positive
- Rockwell Automation Posts Upbeat Q2 Results, Joins EverQuote, DigitalOcean And Other Big Stocks Moving Higher On Tuesday — benzinga May 5, 2026 positive
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session — benzinga May 5, 2026 neutral
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinesevasemten and EDG-750010-K Item 1A: 'We are substantially dependent on the success of our lead product candidates, sevasemten and EDG-7500.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Volatile — 6.5% daily ATR makes tight stops impractical. Position-size conservatively.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $31.58: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10 and A.R:R 1.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Elevated put/call ratio: 17.23; Below-average business quality. Chart setup: RSI 52 mid-range, Bollinger mid-band. Prior stop was $29.50. Score 4.6/10, moderate confidence.
Take-profit target: $37.99 (+19.8% upside). Prior stop was $29.50. Stop-loss: $29.50.
Concentration risk — Pipeline: sevasemten and EDG-7500; Quality below floor (1.5 < 4.0); Value-trap signals (2/5): High leverage (D/E 8.8), Material insider selling (9 sells, 0.12% of cap).
Edgewise Therapeutics, Inc. trades at a P/E of N/A (forward -13.6). TrendMatrix value score: 7.5/10. Verdict: Sell.
18 analysts cover EWTX with a consensus score of 4.2/5. Average price target: $44.
What does Edgewise Therapeutics, Inc. do?Edgewise Therapeutics is a clinical-stage biopharmaceutical company developing small molecule therapies for rare muscle...
Edgewise Therapeutics is a clinical-stage biopharmaceutical company developing small molecule therapies for rare muscle diseases, with lead candidate sevasemten in late-stage trials for Duchenne and Becker muscular dystrophies. No products approved and no revenue to date; $530.1M cash as of Dec 31, 2025.